The study identifies the N-terminal 20 residues of the 20K fragment of myosin S1 heavy chain as an actin-binding site.
No immediate clinical implications; extends mapping of myosin-actin interfaces in animal models.
Myosin subfragment 1 (S1) was covalently labeled with a fluorescent dye, N-[7-(dimethylamino)-4-methyl-3-coumarinyl]maleimide (DACM), and then digested by trypsin to cleave S1 heavy chain into fragments. The DACM-labeled and trypsin-treated S1 was complexed with F-actin and treated with a zero-length cross-linker, 1-ethyl-3[3-(dimethylamino)propyl] carbodiimide (EDC). The cross-linking reaction generated a covalently linked complex of actin and the 20K fragment of S1 heavy chain, which exclusively incorporated the fluorescent dye, to form a fluorescent 65K cross-linked product. The 20K and 65K fluorescent peptides were isolated and purified and then subjected to cyanogen bromide and/or hydroxylamine cleavages. Mapping of fluorescent cleavage products on acrylamide gels revealed that the N-terminal 20 residues of the 20K fragment of S1 heavy chain contained a cross-linking site of actin.
No takes yet. Share an insight, caveat, or question.
Kazuo Sutoh (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: